The prognostic superiority of second-generation androgen receptor signaling inhibitor in patients with non-metastatic castration-resistant prostate cancer

恩扎鲁胺 医学 前列腺癌 雄激素受体 比卡鲁胺 氟他胺 肿瘤科 内科学 雄激素 置信区间 封锁 抗雄激素 雄激素剥夺疗法 醋酸阿比特龙酯 泌尿科 癌症 受体 激素
作者
Taku Naiki,Kiyoshi Takahara,Hiromitsu Watanabe,Keita Nakane,Yosuke Sugiyama,Takuya Koie,Ryoichi Shiroki,Hideaki Miyake,Takahiro Yasui
出处
期刊:Japanese Journal of Clinical Oncology [Oxford University Press]
标识
DOI:10.1093/jjco/hyae155
摘要

Abstract Objective The aim of this study was to compare prognostic outcomes of administering first- or second-generation androgen receptor signaling inhibitors in non-metastatic castration-resistant prostate cancer and to find prognostic indicators. Methods This retrospective study included 198 patients with non-metastatic castration-resistant prostate cancer from 14 institutions associated with Tokai Urologic Oncology Research Seminar. Forty-two patients were treated with combined androgen blockade using first-generation inhibitors (bicalutamide or flutamide), and 156 were treated with second-generation inhibitors (abiraterone/enzalutamide or apalutamide/darolutamide) after primary androgen deprivation therapy failure. We compared survival outcomes of combined androgen blockade using first-generation inhibitors and second-generation inhibitor treatments, and analyzed clinicopathological or serum parameters and survival outcome. Results Combined androgen blockade and second-generation androgen receptor signaling inhibitor groups demonstrated median progression-free survival of 10.2 (95% confidence interval: 5.5–12.3) and 26.0 (95% confidence interval: 21.9–38.4; P < 0.001) months, respectively. Cut-off levels for clinical biomarkers were targeted to <0.2 ng/ml prostate-specific antigen levels 3 months after treatment initiation for non-metastatic castration-resistant prostate cancer; the patient group that achieved this showed better progression-free survival (median 14.7 months, 95% confidence interval: 10.3–23.9 not achieved, median not applicable, 95% confidence interval: 24.6–not applicable achieved; P < 0.00001). Multivariate analysis revealed significant prognostic factors: second-generation androgen receptor signaling inhibitor as first-line treatment (odds ratio: 5.05, 95% confidence interval: 1.54–16.6) and a high hemoglobin level (odds ratio: 2.92, 95% confidence interval: 1.26–6.76). Conclusions Our findings suggested prostate-specific antigen < 0.2 ng/ml after 3 months may be a practical prognostic indicator of survival outcomes in non-metastatic castration-resistant prostate cancer. Patients showing a high hemoglobin level should be intensively treated with second-generation androgen receptor signaling inhibitors rather than combined androgen blockade using first-generation inhibitors.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
华仔的应助被小巧的白容采纳,获得10
1秒前
1秒前
2秒前
徐xx完成签到,获得积分20
2秒前
2秒前
YJDlXX完成签到,获得积分10
2秒前
无极微光的应助被曾诗婷采纳,获得20
3秒前
4秒前
微笑的桐发布了新的文献求助50
4秒前
4秒前
寒山完成签到 ,获得积分10
5秒前
两颗牙发布了新的文献求助10
5秒前
小巧的箴发布了新的文献求助10
6秒前
小鱼发布了新的文献求助20
6秒前
共享精神的应助被CT采纳,获得10
6秒前
6秒前
6秒前
6秒前
swh完成签到 ,获得积分10
6秒前
7秒前
丘比特的应助被价格采纳,获得10
8秒前
酷波er的应助被炒栗子采纳,获得10
8秒前
8秒前
博修发布了新的文献求助10
10秒前
10秒前
11秒前
juston发布了新的文献求助30
11秒前
11秒前
11秒前
Yingzi完成签到,获得积分10
11秒前
12秒前
b7cpx发布了新的文献求助10
12秒前
Jiangpeng完成签到,获得积分10
12秒前
果汁完成签到,获得积分10
12秒前
华无剑的应助被QwQ采纳,获得10
12秒前
文又青发布了新的文献求助10
14秒前
DUMPLINGS发布了新的文献求助10
14秒前
whs发布了新的文献求助10
14秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172269
求助须知:如何正确求助?哪些是违规求助? 9564976
关于积分的说明 21777545
捐赠科研通 7763871
什么是DOI,文献DOI怎么找? 3431205
关于科研通互助平台的介绍 2555075
邀请新用户注册赠送积分活动 2476246